About
Cardionyx is developing an active implant to stimulate baroreceptors for Heart Failure (HF) patients, through a minimally invasive approach. Cardionyx stands at the forefront of medical innovation, poised to address the critical clinical needs of Heart Failure (HF) patients with reduced ejection fraction (HFrEF) through its groundbreaking approach.
With a relentless focus on improving the lives of patients facing diminished life expectancy, frequent hospitalizations, and compromised quality of life (QOL), Cardionyx is developing a first-of-its-kind trans-vessel active implant designed to stimulate electricly baroreceptors, offering a potential game-changer in HF treatment. Unlike conventional therapies, which often leave a significant portion of patients ineligible or poorly managed, Cardionyx redefines the possibilities of intervention. At the core of this innovation lies an implant that leverages venous catheterization for implantation, ensuring a safer and quicker procedure which fits the clinical profile of this patient population.
Another aspect that truly sets Cardionyx apart is its ability to provide personalized therapy coupled with real-time hemodynamic monitoring, allowing for the dynamic regulation of parasympathetic tone. This unique feature enables adjustable upregulation according to the patient's evolving hemodynamics, maximizing efficacy while minimizing adverse events and reducing the likelihood of baroreceptor desensitization.
Funding history · 1 round · $700K total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Cardionyx Heart Science developing?
- Cardionyx Heart Science is developing a first-of-its-kind trans-vessel active implant designed to electrically stimulate baroreceptors for Heart Failure (HF) patients, using a minimally invasive approach.
- When was Cardionyx Heart Science founded?
- Cardionyx Heart Science was founded in November 2020.
- What is the current employee count for Cardionyx Heart Science?
- Cardionyx Heart Science currently has 2 employees.
- What is the total amount of funding raised by Cardionyx Heart Science to date?
- Cardionyx Heart Science has raised a total of $700,000 USD.
- When did Cardionyx Heart Science complete its last funding round and what type was it?
- Cardionyx Heart Science completed a SAFE funding round in August 2023.
- What is the primary sector of Cardionyx Heart Science?
- The primary sector of Cardionyx Heart Science is Health Tech & Life Sciences.
- In which geographic markets does Cardionyx Heart Science operate?
- Cardionyx Heart Science operates in the North America and Americas geographic markets.
- What is the current product stage of Cardionyx Heart Science?
- The current product stage of Cardionyx Heart Science is Research & Development (R&D).
- Does Cardionyx Heart Science hold any patents?
- Yes, Cardionyx Heart Science holds 1 patent.